SAN DIEGO, CA / ACCESS Newswire / April 1, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision-guided medicine, announces a new Anser ® therapeutic drug monitoring (TDM) test for risankizumab (RZB). Anser RZB is a clinically ...

ArianeGroup has successfully carried out the first ignition campaign of the reusable Prometheus® engine on the reusable Themis rocket core stage demonstrator – a key step in providing Europe with the essential technological building blocks for future ...

WASHINGTON (AP) – The Supreme Court unanimously tossed out medical patent claims for Prometheus Laboratories on Tuesday for a test that could help doctors set drug doses for autoimmune diseases like Crohn’s disease, a decision that could affect the ...

Translational Data Inform a Scalable, Noninvasive Test Designed to Identify Treatment-Eligible Patients and Enable Longitudinal Assessment as MASH Therapies Expand Prometheus has been at the forefront of noninvasive liver fibrosis assessment for more than ...

Saliva-based diagnostic detects genes related to the disease and calculates risk. Prometheus has selected DNA Genotek’s Oragene®•DNA product as the sample-collection kit for MyCeliacID™, a saliva-based genetic test. It reportedly detects genes ...

SAN DIEGO, Aug. 31 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary PROMETHEUS® Crohn's Prognostic test. This novel and unique diagnostic represents a significant ...